Siga, U.S. Department of Health and Human Services infectious news

Siga said HHS intends to award a contract for Siga's smallpox antiviral pending resolution of issues related to the company's status with the Small Business Administration. The five-year contract would cover the delivery of 1.7 million courses of the ST-246 smallpox antiviral to the Strategic National Stockpile for about $500 million. HHS has options to expand the contract to include up to an additional 12 million courses, which the company said could bring the total contract value to about $2.8 billion. ST-246 is in Phase II testing. The antiviral compound has Fast Track and Orphan Drug designations in the U.S. ...